Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11218137 | 0.79 | PTPN1 (0.57) | PTPN1EYA3TTR | |
| SCHEMBL2985777 | 0.76 | PTPN1 (0.53) | PTPN1EYA3TTR | |
| SCHEMBL2903922 | 0.74 | CYP1B1 (0.43) | TSHRALDH1A1 | |
| SCHEMBL9113894 | 0.74 | MAPT (0.44) | TSHRPTK2BALDH1A1 | |
| SCHEMBL13049676 | 0.74 | PTPN1 (0.55) | PTPN1EYA3TTR | |
| SCHEMBL24026894 | 0.73 | PTPN1 (0.51) | PTPN1EYA3TTR | |
| SCHEMBL669127 | 0.73 | PTPN1 (0.54) | PTPN1EYA3TTR | |
| SCHEMBL11050071 | 0.72 | PTPN1 (0.49) | PTPN1EYA3TTR | |
| SCHEMBL3352216 | 0.72 | PTPN1 (0.50) | PTPN1EYA3TTR | |
| SCHEMBL21555485 | 0.72 | PTPN1 (0.52) | PTPN1EYA3TTRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7837981-B2 | Methods for imaging soluble A-beta | GENERAL ELECTRIC COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1631561-B1 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID | GEN ELECTRIC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7727511-B2 | Agents for imaging soluble a-beta | GENERAL ELECTRIC COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070189967-A1 | AGENTS FOR IMAGING SOLUBLE A-BETA | GENERAL ELECTRIC COMPANY (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070140960-A1 | METHODS FOR IMAGING SOLUBLE A-BETA | GENERAL ELECTRIC COMPANY (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1631561-A2 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID | GENERAL ELECTRIC COMPANY (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004100998-A2 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID | GENERAL ELECTRIC COMPANY (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040223909-A1 | Compositions and methods for non-invasive imaging of soluble beta-amyloid | GENERAL ELECTRIC COMPANY | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040223909-A1 | Compositions and methods for non-invasive imaging of soluble beta-amyloid | APP, APBA1, BACE1 | PTPN1 3226/4885TSHR 3915/4885PTK2B 2126/4885 |
| US-20070140960-A1 | METHODS FOR IMAGING SOLUBLE A-BETA | APBA1, APP, FABP7 | PTPN1 4473/4885TSHR 3301/4885PTK2B 1756/4885 |
| US-20070189967-A1 | AGENTS FOR IMAGING SOLUBLE A-BETA | APBA1, APP, FABP7 | PTPN1 4345/4885TSHR 2981/4885PTK2B 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.